PL3609894T3 - Krystaliczna sól sodowa kwasu 5-metylo-(6s)-tetrahydrofoliowego - Google Patents
Krystaliczna sól sodowa kwasu 5-metylo-(6s)-tetrahydrofoliowegoInfo
- Publication number
- PL3609894T3 PL3609894T3 PL18715594.0T PL18715594T PL3609894T3 PL 3609894 T3 PL3609894 T3 PL 3609894T3 PL 18715594 T PL18715594 T PL 18715594T PL 3609894 T3 PL3609894 T3 PL 3609894T3
- Authority
- PL
- Poland
- Prior art keywords
- methyl
- sodium salt
- tetrahydrofolic acid
- crystalline sodium
- crystalline
- Prior art date
Links
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164349 | 2017-03-31 | ||
| PCT/EP2018/057900 WO2018178141A1 (en) | 2017-03-31 | 2018-03-28 | Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3609894T3 true PL3609894T3 (pl) | 2024-12-16 |
Family
ID=58464443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18715594.0T PL3609894T3 (pl) | 2017-03-31 | 2018-03-28 | Krystaliczna sól sodowa kwasu 5-metylo-(6s)-tetrahydrofoliowego |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11185545B2 (pl) |
| EP (1) | EP3609894B1 (pl) |
| JP (1) | JP7285785B2 (pl) |
| KR (1) | KR102665004B1 (pl) |
| CN (1) | CN110475778A (pl) |
| AU (1) | AU2018246265B2 (pl) |
| CA (1) | CA3058287A1 (pl) |
| DK (1) | DK3609894T3 (pl) |
| ES (1) | ES2989869T3 (pl) |
| FI (1) | FI3609894T3 (pl) |
| HU (1) | HUE068578T2 (pl) |
| PL (1) | PL3609894T3 (pl) |
| PT (1) | PT3609894T (pl) |
| RU (1) | RU2019133594A (pl) |
| WO (1) | WO2018178141A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115611899B (zh) * | 2022-10-25 | 2024-06-04 | 无锡紫杉药业股份有限公司 | 一种l-5-甲基四氢蝶酸的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124452A (en) * | 1978-07-10 | 1992-06-23 | Bioresearch S.P.A. | Process for producing d,1-5-methyltetrahydrofolic acid and its salts |
| IT1229517B (it) | 1989-01-31 | 1991-09-03 | Bioresearch Spa | Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. |
| CH686369A5 (de) | 1994-05-09 | 1996-03-15 | Eprova Ag | Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure. |
| ZA968485B (en) | 1995-11-01 | 1997-05-20 | Lonza Ag | Process for preparing nicotinamide |
| CH689831A5 (de) | 1995-11-07 | 1999-12-15 | Eprova Ag | Stabile kristalline Tetrahydrofolsaeure-Salze. |
| CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| JP5856372B2 (ja) | 2008-02-20 | 2016-02-09 | グノーシス・エツセ・ピー・アー | 葉酸塩、これらの組成物および使用 |
| WO2013025203A1 (en) * | 2011-08-16 | 2013-02-21 | Watson Laboratories, Inc. | Resolution of tetrahydrofolic acid derivatives |
| ITMI20111808A1 (it) * | 2011-10-05 | 2013-04-06 | Ati S R L | Composizione alimentare priva di glutine e prodotti alimentari con essa preparati |
| IN2014DN06942A (pl) | 2012-01-20 | 2015-04-10 | Lianyungang Jinkang Hexin Pharmaceutical Co Ltd | |
| CN104557937B (zh) * | 2012-01-20 | 2017-03-08 | 连云港金康和信药业有限公司 | (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法 |
| US20160207925A1 (en) * | 2013-12-31 | 2016-07-21 | Gianni Fracchia | L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof |
| WO2015193778A1 (en) * | 2014-06-16 | 2015-12-23 | Mylan Laboratories Ltd. | Crystalline form of levomefolate calcium |
-
2018
- 2018-03-28 ES ES18715594T patent/ES2989869T3/es active Active
- 2018-03-28 CN CN201880020919.3A patent/CN110475778A/zh active Pending
- 2018-03-28 CA CA3058287A patent/CA3058287A1/en active Pending
- 2018-03-28 AU AU2018246265A patent/AU2018246265B2/en active Active
- 2018-03-28 WO PCT/EP2018/057900 patent/WO2018178141A1/en not_active Ceased
- 2018-03-28 RU RU2019133594A patent/RU2019133594A/ru unknown
- 2018-03-28 EP EP18715594.0A patent/EP3609894B1/en active Active
- 2018-03-28 DK DK18715594.0T patent/DK3609894T3/da active
- 2018-03-28 KR KR1020197031538A patent/KR102665004B1/ko active Active
- 2018-03-28 JP JP2019553824A patent/JP7285785B2/ja active Active
- 2018-03-28 HU HUE18715594A patent/HUE068578T2/hu unknown
- 2018-03-28 PT PT187155940T patent/PT3609894T/pt unknown
- 2018-03-28 US US16/498,549 patent/US11185545B2/en active Active
- 2018-03-28 PL PL18715594.0T patent/PL3609894T3/pl unknown
- 2018-03-28 FI FIEP18715594.0T patent/FI3609894T3/fi active
-
2021
- 2021-07-28 US US17/387,077 patent/US12048700B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110475778A (zh) | 2019-11-19 |
| KR102665004B1 (ko) | 2024-05-09 |
| EP3609894B1 (en) | 2024-07-17 |
| US11185545B2 (en) | 2021-11-30 |
| PT3609894T (pt) | 2024-08-29 |
| FI3609894T3 (fi) | 2024-10-23 |
| US20220016121A1 (en) | 2022-01-20 |
| DK3609894T3 (da) | 2024-09-09 |
| JP7285785B2 (ja) | 2023-06-02 |
| CA3058287A1 (en) | 2018-10-04 |
| WO2018178141A1 (en) | 2018-10-04 |
| US12048700B2 (en) | 2024-07-30 |
| EP3609894A1 (en) | 2020-02-19 |
| JP2020512383A (ja) | 2020-04-23 |
| ES2989869T3 (es) | 2024-11-28 |
| RU2019133594A3 (pl) | 2021-07-21 |
| RU2019133594A (ru) | 2021-04-30 |
| AU2018246265A1 (en) | 2019-11-14 |
| AU2018246265B2 (en) | 2022-07-07 |
| KR20190136029A (ko) | 2019-12-09 |
| HUE068578T2 (hu) | 2025-01-28 |
| US20200030333A1 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804870B (en) | Acid addition salts of piperazine derivatives | |
| IL269170B (en) | The hemisulfate salt of tetrahydrofolic acid 5, 10 methylene (6r) | |
| TWI560185B (en) | Acid addition salt of trk inhibitor compound | |
| EP3345907A4 (en) | NOVEL PYRAZOLO [3,4-D] PYRIMIDINE COMPOUND OR SALT THEREOF | |
| IL273579A (en) | Salts of pyrrolothrizine compounds used as tem inhibitors. | |
| EP3190112A4 (en) | Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof | |
| IL259998A (en) | Polymorphic crystalline forms of obeticholic acid | |
| IL269626A (en) | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| SI3749673T1 (sl) | Kristalinična oblika biktegravir natrija | |
| HUE051640T2 (hu) | Húgysav nátriumsó transzporter inhibitor és kristályos formája | |
| EP3199529A4 (en) | Salt of dicarboxylic acid compound | |
| DK3398946T3 (da) | Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme | |
| HUE068578T2 (hu) | 5-Metil-(6S)-tetrahidrofolsav kristályos nátriumsója | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| DK3817813T3 (da) | Krystallinske salte af 5-methyl-(6s)-tetrahydrofolsyre og l-leucinethylester | |
| DK3817814T3 (da) | Krystallinske salte af 5-methyl-(6s)-tetrahydrofolsyre og l-valinethylester | |
| FIC20170021I1 (fi) | deoksikoolihapon natriumsuola | |
| PT3749673T (pt) | Forma cristalina de bictegravir sódico | |
| HUE064730T2 (hu) | 5-Metil-(6S)-tetrahidrofolsavat és L-izoleucin-etilésztert tartalmazó kristályos só | |
| PL3818048T3 (pl) | Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę | |
| HUP1600613A2 (en) | Crystalline forms of sacubitril hemicalcium salt |